Form 4: RAPT Therapeutics Director, Wendye Robbins, Acquires Stock Options in Lieu of Cash Retainer

Wendye Robbins, a director at RAPT Therapeutics, acquired stock options in lieu of a cash retainer, signaling continued alignment with the company's long-term performance.

Summary

• On March 28, 2024, Wendye Robbins, a director at RAPT Therapeutics, acquired 6,925 stock options.
• The options have an exercise price of $8.98.
• These options were granted in lieu of a $52,500 annual cash retainer for board service.
• The options vest in four equal quarterly installments starting March 31, 2024, contingent on continued service as a director.
• Following the transaction, Ms. Robbins directly owns 6,925 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a standard transaction (granting of stock options to a director). It suggests confidence in the company's future, as the director is willing to accept equity in lieu of cash. Therefore, the sentiment is moderately positive.

Positives

• The acquisition of stock options by a director aligns their interests with those of shareholders, incentivizing them to work towards the company's success.
• Choosing stock options over cash retainers demonstrates confidence in the company's future prospects.

Future Outlook

The document does not contain explicit forward-looking statements, but the granting of stock options suggests an expectation of future value creation.

Industry Context

Granting stock options to board members is a common practice in the biotech industry to align their interests with shareholders and conserve cash, especially for companies in the development stage like RAPT Therapeutics.

Comparison to Industry Standards

• Granting stock options in lieu of cash compensation is a common practice among biotech companies, especially those that are pre-revenue or early-stage, to conserve cash.
• The size of the option grant, valued at $52,500, appears to be within the typical range for director compensation in similar-sized biotech firms.
• Comparing to companies like Arcus Biosciences or Nurix Therapeutics, which also grant equity to directors, the structure and vesting schedule are fairly standard.

Stakeholder Impact

• Shareholders may view the granting of stock options positively, as it aligns the director's interests with theirs.
• Employees may see it as a sign of confidence in the company's future.

Key Dates